You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Coiled Therapeutics reports enhanced efficacy for AO-252 and accelerates transition to dose expansion

CenExel appoints Dr. Sy Pretorius as CEO

IDEOlogy Health and West Cancer Center partner to advance patient-centred oncology education and care

Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints

Gilead to acquire Tubulis to expand ADC oncology capabilities

FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer

Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP

Aelis Farma secures EUR458k France 2030 grant to advance metabolic disease programme

Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency

NeuroSense's PrimeC composition receives Brazilian patent

Akeso reports updated data on cadonilimab combination therapy in PD-(L)1 inhibitor-resistant advanced NSCLC data

AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer

Caliway to present preclinical data on CBL-514 in combination with GLP-1R therapy at ADA 2026 Scientific Sessions

Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development

Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026